A pharmaceutical quality crisis involving nitrosamine contamination began in 2018 with the discovery of N-nitrosodimethylamine, a type of nitrosamine, in angiotensin receptor blocker medicines, triggering global recalls, regulatory investigations, and a fundamental reassessment of pharmaceutical quality systems. The crisis did not expose a single manufacturing failure but structural weakness in how the pharmaceutical sector predicts, identifies, and manages chemical risk.
Nitrosamines are a class of compounds that can form when amines react with nitrosating agents under favorable conditions. Many nitrosamines are classified as probable human carcinogens based on animal studies; even trace-level exposure in medicines warrants careful control.
What initially appeared to be an isolated contamination event has since evolved into one of the most consequential quality challenges modern pharmaceutical manufacturing has faced. More importantly, it has forced the industry to confront an uncomfortable reality: long-standing assumptions about impurity control, formulation design, and life-cycle risk assessment are no longer sufficient in an era of ultra trace analytical detection and increasingly complex global supply chains.
Initially, nitrosamines were considered contaminants arising primarily during active pharmaceutical ingredient (API) synthesis. Investigations focused on secondary or tertiary amines, nitrite-containing reagents, solvent recovery practices, and vulnerable process conditions. Manufacturers implemented process changes and tighter raw material controls to mitigate identified risks. Yet as analytical technologies became more sensitive, it became clear that the problem extended well beyond API chemistry.
Nitrosamines can also form throughout the drug product life cycle, including during formulation, manufacture, and long-term storage. This realization fundamentally changed scientific thinking about impurity formation. The industry could no longer regard excipients as chemically inert components with limited relevance to impurity formation. Excipients, degradation pathways, packaging interactions, microenvironmental pH, moisture content, and storage conditions all became potential contributors to nitrosamine generation.
Beginning around 2020, the emergence of nitrosamine drug substance–related impurities (NDSRIs) reinforced this shift. Unlike externally introduced contaminants, NDSRIs may form in situ through interactions between APIs and formulation components during manufacturing or shelf life. Their formation depends on a complex interplay of chemistry, process conditions, and product design. In practical terms, nitrosamine control has evolved from a narrow process chemistry issue into a broader challenge requiring integration across synthetic chemistry, formulation science, analytical chemistry, toxicology, and regulatory strategy.
That broader implication may ultimately become the most important legacy of the nitrosamine experience. The pharmaceutical sector has historically relied heavily on retrospective quality assurance such as detect a problem, investigate the root cause, implement corrective actions, and validate the revised process. Nitrosamines suggest that this model is becoming increasingly inadequate. Modern pharmaceutical systems generate chemical interactions too complex to manage solely through traditional validation frameworks and end-product testing.
In many ways, nitrosamines represent the first truly global demonstration of what happens when analytical sensitivity advances faster than predictive scientific capability. Laboratories can now detect contaminants at parts-per-billion levels, but the industry’s ability to mechanistically predict how those contaminants form often remains limited. This gap between detection and prediction has pushed companies into reactive mitigation strategies rather than proactive prevention.
Regulators worldwide have responded by expanding guidance related to nitrosamine risk assessments, confirmatory testing, acceptable intake limits, and life-cycle management expectations. At the same time, they have acknowledged the difficult reality that complete elimination of nitrosamine risk may not always be technically or economically feasible without jeopardizing medicine availability. Some mitigation strategies require extensive reformulation or process redesign that can disrupt manufacturing continuity. Balancing theoretical carcinogenic risk with uninterrupted patient access has become one of the defining policy challenges of modern pharmaceutical regulation.
The experience with nitrosamines also raises broader questions for the pharmaceutical chemistry community. If they emerged from interactions previously considered minimal risk or poorly understood, what other trace-level impurity mechanisms remain undiscovered? As analytical technologies continue advancing, the industry will almost certainly encounter additional contaminant classes that challenge current quality paradigms. The real lesson from nitrosamines may therefore extend well beyond nitrosamines themselves.
This challenge should serve as a call to the global chemistry community. Pharmaceutical chemistry can no longer operate with rigid boundaries between process development, formulation science, analytical chemistry, and toxicology. The next generation of impurity control will require predictive, systems-level thinking rather than isolated, discipline-specific solutions. Mechanistic understanding of degradation pathways, reactive intermediates, and excipient interactions must become integrated much earlier in drug development.
The industry also needs stronger precompetitive scientific collaboration to accelerate understanding of nitrosamine formation mechanisms and to improve predictive risk assessment. At present, companies often investigate nitrosamine mechanisms independently, duplicating efforts while generating fragmented datasets. Shared mechanistic knowledge platforms, harmonized analytical approaches, and collaborative predictive modeling could advance scientific understanding while reducing unnecessary regulatory uncertainty. Without such cooperation, the industry risks repeating the same reactive cycle when future impurity challenges emerge.
Ultimately, nitrosamines have reshaped how the pharmaceutical industry thinks about trace impurities and patient safety. What began as a recall-driven crisis has evolved into a broader reckoning with the limitations of traditional quality control systems. The companies best prepared for the future will not simply be those capable of detecting impurities at lower concentrations but those capable of anticipating chemical risks before they reach the patient.
Credit:
Courtesy of Kiran Kumar Kurella
Nitrosamines may therefore be remembered not merely as a contamination problem but as the moment that pharmaceutical chemistry was forced to transition from reactive control toward predictive science.
Kiran Kumar Kurella is a research scholar in the chemistry department at GITAM (Gandhi Institute of Technology and Management) School of Science in Visakhapatnam, India, and a senior manager at Caponex Labs.
Views expressed are those of the author and not necessarily those of C&EN or ACS.
Do you have a story you want to share with the chemistry community? Send your idea or an 800-word submission to [email protected].
